Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 210

1.

Relationships between Adipose Mitochondrial Function, Serum Adiponectin, and Insulin Resistance in Persons with HIV after 96 weeks of Antiretroviral Therapy.

Hulgan T, Ramsey BS, Koethe JR, Samuels DC, Gerschenson M, Libutti DE, Sax PE, Daar ES, Mccomsey GA, Brown TT.

J Acquir Immune Defic Syndr. 2018 Nov 29. doi: 10.1097/QAI.0000000000001926. [Epub ahead of print]

PMID:
30531304
2.

Two-drug regimens for treatment of naïve HIV-1 infection and as maintenance therapy.

Corado KC, Caplan MR, Daar ES.

Drug Des Devel Ther. 2018 Nov 1;12:3731-3740. doi: 10.2147/DDDT.S140767. eCollection 2018. Review.

3.

Substance Use and Adherence to HIV Preexposure Prophylaxis for Men Who Have Sex with Men1.

Hoenigl M, Jain S, Moore D, Collins D, Sun X, Anderson PL, Corado K, Blumenthal JS, Daar ES, Milam J, Dubé MP, Morris S; California Collaborative Treatment Group 595 Team.

Emerg Infect Dis. 2018 Dec;24(12). doi: 10.3201/eid2412.180400.

4.

Sexual Risk Compensation in a Pre-exposure Prophylaxis Demonstration Study Among Individuals at Risk of HIV.

Milam J, Jain S, Dubé MP, Daar ES, Sun X, Corado K, Ellorin E, Blumenthal J, Haubrich R, Moore DJ, Morris SR; CCTG Team.

J Acquir Immune Defic Syndr. 2019 Jan 1;80(1):e9-e13. doi: 10.1097/QAI.0000000000001885.

PMID:
30334877
5.

Antiretroviral switch studies do matter.

Daar ES, Ruane P, DeJesus E, Stellbrink HJ, Molina JM.

Lancet HIV. 2018 Oct;5(10):e546. doi: 10.1016/S2352-3018(18)30259-5. Epub 2018 Oct 8. No abstract available.

PMID:
30319119
6.

Trajectories and Predictors of Longitudinal Preexposure Prophylaxis Adherence Among Men Who Have Sex With Men.

Pasipanodya EC, Jain S, Sun X, Blumenthal J, Ellorin E, Corado K, Dube MP, Daar ES, Morris SR, Moore DJ; California Collaborative Treatment Group (CCTG) TAPIR Study Team.

J Infect Dis. 2018 Oct 5;218(10):1551-1559. doi: 10.1093/infdis/jiy368.

PMID:
30295803
7.

Population Pharmacokinetics of Lopinavir/Ritonavir: Changes Across Formulations and Human Development From Infancy Through Adulthood.

Yang J, Nikanjam M, Best BM, Pinto J, Chadwick EG, Daar ES, Havens PL, Rakhmanina N, Capparelli EV.

J Clin Pharmacol. 2018 Dec;58(12):1604-1617. doi: 10.1002/jcph.1293. Epub 2018 Sep 25.

PMID:
30252146
8.

Safety and Impact of Low-Dose Methotrexate on Endothelial Function and Inflammation in Individuals with Treated Human Immunodeficiency Virus: AIDS Clinical Trials Group Study A5314.

Hsue PY, Ribaudo HJ, Deeks SG, Bell T, Ridker PM, Fichtenbaum C, Daar ES, Havlir D, Yeh E, Tawakol A, Lederman M, Currier JS, Stein JH.

Clin Infect Dis. 2018 Sep 14. doi: 10.1093/cid/ciy781. [Epub ahead of print]

PMID:
30219823
9.

Switching to coformulated rilpivirine (RPV), emtricitabine (FTC) and tenofovir alafenamide from either RPV, FTC and tenofovir disoproxil fumarate (TDF) or efavirenz, FTC and TDF: 96-week results from two randomized clinical trials.

Hagins D, Orkin C, Daar ES, Mills A, Brinson C, DeJesus E, Post FA, Morales-Ramirez J, Thompson M, Osiyemi O, Rashbaum B, Stellbrink HJ, Martorell C, Liu H, Liu YP, Porter D, Collins SE, SenGupta D, Das M.

HIV Med. 2018 Nov;19(10):724-733. doi: 10.1111/hiv.12664. Epub 2018 Aug 12.

10.

CD8+ Cytotoxic T Lymphocyte Responses and Viral Epitope Escape in Acute HIV-1 Infection.

Kim J, De La Cruz J, Lam K, Ng H, Daar ES, Balamurugan A, Yang OO.

Viral Immunol. 2018 Sep;31(7):525-536. doi: 10.1089/vim.2018.0040. Epub 2018 Jul 30.

PMID:
30059271
11.

Efficacy and safety of switching to fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide from boosted protease inhibitor-based regimens in virologically suppressed adults with HIV-1: 48 week results of a randomised, open-label, multicentre, phase 3, non-inferiority trial.

Daar ES, DeJesus E, Ruane P, Crofoot G, Oguchi G, Creticos C, Rockstroh JK, Molina JM, Koenig E, Liu YP, Custodio J, Andreatta K, Graham H, Cheng A, Martin H, Quirk E.

Lancet HIV. 2018 Jul;5(7):e347-e356. doi: 10.1016/S2352-3018(18)30091-2. Epub 2018 Jun 18.

PMID:
29925490
12.

Brain neurotransmitter transporter/receptor genomics and efavirenz central nervous system adverse events.

Haas DW, Bradford Y, Verma A, Verma SS, Eron JJ, Gulick RM, Riddler SA, Sax PE, Daar ES, Morse GD, Acosta EP, Ritchie MD.

Pharmacogenet Genomics. 2018 Jul;28(7):179-187. doi: 10.1097/FPC.0000000000000341.

PMID:
29847509
13.

Randomized Trial of a Health Coaching Intervention to Enhance Retention in Care: California Collaborative Treatment Group 594.

Corado K, Jain S, Morris S, Dube MP, Daar ES, He F, Aldous JL, Sitapati A, Haubrich R, Milam J, Karris MY.

AIDS Behav. 2018 Aug;22(8):2698-2710. doi: 10.1007/s10461-018-2132-3.

PMID:
29725790
14.

Next generation fixed dose combination pharmacotherapies for treating HIV.

Caplan MR, Daar ES, Corado KC.

Expert Opin Pharmacother. 2018 Apr;19(6):589-596. doi: 10.1080/14656566.2018.1450866. Epub 2018 Mar 20. Review.

PMID:
29557204
15.

Randomized Controlled Trial of Daily Text Messages to Support Adherence to Preexposure Prophylaxis in Individuals at Risk for Human Immunodeficiency Virus: The TAPIR Study.

Moore DJ, Jain S, Dubé MP, Daar ES, Sun X, Young J, Corado K, Ellorin E, Milam J, Collins D, Blumenthal J, Best BM, Anderson P, Haubrich R, Morris SR.

Clin Infect Dis. 2018 May 2;66(10):1566-1572. doi: 10.1093/cid/cix1055.

PMID:
29228144
16.

Efavirenz Therapeutic Range in HIV-1 Treatment-Naive Participants.

Bednasz CJ, Venuto CS, Ma Q, Daar ES, Sax PE, Fischl MA, Collier AC, Smith KY, Tierney C, Yang Y, Wilding GE, Morse GD.

Ther Drug Monit. 2017 Dec;39(6):596-603. doi: 10.1097/FTD.0000000000000443.

17.

Baseline Cigarette Smoking Status as a Predictor of Virologic Suppression and CD4 Cell Count During One-Year Follow-Up in Substance Users with Uncontrolled HIV Infection.

Winhusen T, Feaster DJ, Duan R, Brown JL, Daar ES, Mandler R, Metsch LR.

AIDS Behav. 2018 Jun;22(6):2026-2032. doi: 10.1007/s10461-017-1928-x.

PMID:
29030717
18.

Race/Ethnicity and the Pharmacogenetics of Reported Suicidality With Efavirenz Among Clinical Trials Participants.

Mollan KR, Tierney C, Hellwege JN, Eron JJ, Hudgens MG, Gulick RM, Haubrich R, Sax PE, Campbell TB, Daar ES, Robertson KR, Ventura D, Ma Q, Edwards DRV, Haas DW; AIDS Clinical Trials Group.

J Infect Dis. 2017 Sep 1;216(5):554-564. doi: 10.1093/infdis/jix248.

19.

Bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection (GS-US-380-1489): a double-blind, multicentre, phase 3, randomised controlled non-inferiority trial.

Gallant J, Lazzarin A, Mills A, Orkin C, Podzamczer D, Tebas P, Girard PM, Brar I, Daar ES, Wohl D, Rockstroh J, Wei X, Custodio J, White K, Martin H, Cheng A, Quirk E.

Lancet. 2017 Nov 4;390(10107):2063-2072. doi: 10.1016/S0140-6736(17)32299-7. Epub 2017 Aug 31.

PMID:
28867497
20.

Novel approaches to HIV therapy.

Daar ES.

F1000Res. 2017 May 31;6:759. doi: 10.12688/f1000research.11164.1. eCollection 2017. Review.

Supplemental Content

Loading ...
Support Center